Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma

NCT: NCT05479708 · ACTIVE_NOT_RECRUITING

NCT IDNCT05479708
StatusACTIVE_NOT_RECRUITING
Start Date2023-08-09
Completion2028-08

Brief Summary

Short-term relapse and poor survival are prevalent in patients with pancreatic adenocarcinoma (PAAD) after surgeries. Despite the importance of adjuvant treatments for resected PAAD patients, there is currently no suitable biomarker to identify those individuals with high risk of recurrence and inform therapeutic decision making. In this study, we aim to examine whether postoperative circulating tumor DNA (ctDNA) could be used as a biomarker for early detection of minimal residual disease (MRD) and predicting relapse in resected PAAD through high-depth targeted next-generation sequencing.

Frequently Asked Questions

What is ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma?

ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma is a clinical trial registered under NCT05479708. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05479708?

The current status of NCT05479708 (ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma) is: ACTIVE_NOT_RECRUITING.

When did ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma start?

ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma started on 2023-08-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑